IFPA - Inovatyvios farmacijos pramonės asociacija

What IFPA - Inovatyvios farmacijos pramonės asociacija does

IFPA (Inovatyvios farmacijos pramonės asociacija / Innovative Pharmaceutical Industry Association) is a Lithuanian non-profit industry association founded in 1997 that represents 18 innovative pharmaceutical companies operating in Lithuania. It functions as the country's national member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and maintains affiliated relationships with Vaccines Europe, the Innovative Medicines Initiative (IMI), the European Biopharmaceutical Enterprises (EBE), and the European Medicines Verification Organisation (EMVO). The association's mandate is to advocate for faster patient access to innovative medicines, maintain industry self-regulation through an Ethics Code and a Disclosure Code governing transfers of value to healthcare professionals, promote clinical research, and facilitate dialogue between the pharmaceutical industry, healthcare institutions, and Lithuanian policymakers. Its primary stakeholders are its member companies (international pharma corporations with Lithuanian operations) and secondarily the Ministry of Health, National Cancer Institute, National Cancer Center, healthcare professionals, and patient communities.

IFPA's core offerings are non-commercial in nature: the official information portal (ifpa.lt) providing news, publications, and member information; the Marketing Ethics Code and Disclosure Code that codify industry conduct; the annual W.A.I.T. (Waiting to Access Innovative Therapies) indicator study, which is produced by IQVIA for EFPIA and provides country-level medicine availability data; and active participation in pan-European campaigns such as #WeWontRest and Europe's Choice. The association has no proprietary technology platform, no AI/ML capabilities, and no commercial product lines — its "outputs" are policy positions, ethical guidelines, research findings, and industry-news communications distributed via website, social media, press releases, expert commentaries, and conferences.

IFPA does not generate commercial revenue; it is funded through membership dues from its 18 pharmaceutical company members and operates under Lithuanian law as a non-profit organization. The association is governed by a member-elected board (last elected in December 2025, with prior elections in 2023) and is led by Director Jūra Smilgaitė, appointed in late 2021/early 2022, succeeding former directors Leonas Kalėtinas and Agnė Gaižauskienė. Key operational data points include: industry investments by IFPA members in Lithuania exceeding 190 million EUR cumulatively, with 36 million EUR in 2020 and 34 million EUR in 2019; a 2017 recognition from Lithuania's Special Investigation Service (STT) for contribution to anti-corruption environment; and recent strategic expansion into oncology partnerships signed with the National Cancer Institute (NVI) and National Cancer Center (NVC) in July 2026.

Name

IFPA - Inovatyvios farmacijos pramonės asociacija

Legal name

Inovatyvios farmacijos pramonės asociacija

Website

https://ifpa.lt

Company type

Private

Founded year

1997

Operating status

Operating

Headcount range

1–10 employees

Short description

IFPA is a Lithuanian non-profit industry association founded in 1997 representing 18 innovative pharmaceutical companies as Lithuania's national member of EFPIA. It advocates for patient access to innovative medicines, maintains industry ethics and disclosure codes, and engages in healthcare policy dialogue.

Ownership category

akta.pro rank

Headquarters

HQ city

Vilnius

HQ country

Lithuania

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Distribution channels1 record

Marketing channels5 records

Core offering

IFPA is a Lithuanian non-profit industry association that represents 18 innovative pharmaceutical companies operating in Lithuania. Its core activities include advocating for faster patient access to innovative medicines, maintaining self-regulatory Ethics and Disclosure codes for member companies, publishing policy research such as the W.A.I.T. Indicator study on medicine availability, and facilitating partnerships between the pharmaceutical industry, healthcare institutions, and government bodies. The association serves as Lithuania's national member of EFPIA.

Product overview

IFPA (Inovatyvios farmacijos pramonės asociacija) is the Lithuanian Innovative Pharmaceutical Industry Association representing companies that develop and manufacture innovative medicines. The association serves as the national representative of EFPIA (European Federation of Pharmaceutical Industries and Associations) and Vaccines Europe in Lithuania. IFPA's portfolio includes industry self-regulation through ethical codes (Ethics Code and Disclosure Code), policy advocacy for improving access to innovative medicines, research collaboration initiatives such as the W.A.I.T. study on medicine availability, and facilitating partnerships between the pharmaceutical industry, healthcare institutions, and patient organizations. The association does not offer commercial software products but provides a public information portal with news, publications, and resources on pharmaceutical policy and clinical trials.

Differentiator

Problem solved

Functional benefit

Products and services

• Marketing Ethics Code (Vaistų rinkodaros etikos kodeksas) Self-regulatory code governing pharmaceutical company promotional activities in Lithuania, ensuring ethical practices and preventing conflicts of interest in interactions with healthcare professionals. Adopted by all IFPA member companies.
• Disclosure Code (Atskleidimo kodeksas) Transparency code requiring IFPA member companies to publicly disclose transfers of value to healthcare professionals and healthcare organisations, promoting industry transparency and accountability.
• W.A.I.T. Indicator (Waiting to Access Innovative Therapies) Annual pan-European research study analysing availability and reimbursement timelines for innovative medicines across European countries, conducted by IQVIA for EFPIA and published with Lithuanian country-level data by IFPA.

Quantifiable outcome

• 37 innovative medicines now available in Lithuania's compensation list (up from 28)
• +1 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Seven partnerships are on record, tiered flagship, core and minor.

• Nacionalinis vėžio institutas (NVI - National Cancer Institute)flagshipStrategic or Co-development Partner · 1 July 2026IFPA and NVI signed a cooperation declaration to strengthen oncology collaboration. Focus areas include personalized medicine integration, radiopharmacy cooperation, and involvement of national and international research centers in fundamental and applied biomedical research in oncology.
• Nacionalinis vėžio centras (NVC - National Cancer Center)flagshipStrategic or Co-development Partner · 1 July 2026IFPA and NVC signed a cooperation declaration alongside NVI. Goals include accelerating personalized medicine implementation in Lithuania, improving health data management, developing digital solutions and biobank infrastructure, and strengthening Lithuania's international visibility and competitiveness.
• Lithuanian Ministry of HealthcoreStrategic or Co-development Partner · 1 January 2015Ministry of Health and EFPIA (with IFPA as Lithuanian member) signed an agreement on joint work to ensure innovation accessibility in the health sector and more efficient patient treatment with new medicines.
• EFPIA (European Federation of Pharmaceutical Industries and Associations)coreStrategic or Co-development PartnerEFPIA is the European federation representing the pharmaceutical industry. IFPA is the Lithuanian national member of EFPIA, adhering to all EFPIA codes including the Marketing Ethics Code and Disclosure Code. IFPA participates in EFPIA events and initiatives including the Europe's Choice campaign.
• Vaccines EuropecoreStrategic or Co-development PartnerVaccines Europe is the vaccines division of EFPIA, representing vaccine manufacturers in Europe. IFPA maintains affiliation through its EFPIA membership.
• IMI (Innovative Medicines Initiative)minorStrategic or Co-development PartnerEU public-private partnership for health research and innovation. IFPA connects Lithuanian stakeholders to IMI initiatives through EFPIA membership.
• EBE (European Biopharmaceutical Enterprises)minorStrategic or Co-development PartnerEuropean association representing biotech and biopharmaceutical companies. IFPA connects members through EFPIA network.

Scale indicators10 records

Recent moves6 records

Expansion highlights4 records

Regional players

• JPMA (Japan Pharmaceutical Manufacturers Association): Japan's national association of innovative pharmaceutical manufacturers. A regionally distinct peer with an analogous mandate — advocacy for innovative medicines, ethics codes, and R&D promotion — but operating in a fundamentally different health system.
• Medicines Australia: Australia's national innovative pharmaceutical industry association. Directly comparable in structure and remit to IFPA, but operating in a different (Australian) reimbursement and policy environment, making it a regional rather than direct competitor.

Direct peers

• Vaccines Europe: The vaccines-focused operating division of EFPIA, with which IFPA is directly affiliated. Vaccines Europe is a peer in the sense of operating under the same EFPIA umbrella and addressing overlapping Lithuanian/EU vaccine policy topics.
• EFPIA (European Federation of Pharmaceutical Industries and Associations): The pan-European innovative pharma industry association of which IFPA is the Lithuanian national member. EFPIA sets the codes (Ethics, Disclosure) and W.A.I.T. methodology that IFPA implements locally, making it the closest structural and functional peer.
• LIF (Läkemedelsindustriföreningen, Sweden): Sweden's innovative pharmaceutical industry association and a fellow EFPIA national member. LIF is a comparable Nordic/Baltic-region association focused on innovative medicine access and EFPIA-aligned ethics codes.
• vfa (Verband forschender Arzneimittelhersteller): Germany's research-based pharma industry association. Like IFPA, vfa represents innovative pharma manufacturers domestically and through EFPIA, and runs parallel advocacy on reimbursement, clinical trials, and ethical marketing.
• ABPI (Association of the British Pharmaceutical Industry): The UK national trade association for innovative pharmaceutical companies. ABPI is a direct structural analogue to IFPA — both are national member associations under EFPIA, negotiating access and code compliance with their respective health authorities.

Broad incumbents

• PhRMA (Pharmaceutical Research and Manufacturers of America): The US national association for innovative biopharmaceutical research companies. Same overarching mission (advocacy for innovative medicine access, ethics, and research), but operating in a much larger, more diverse market and regulatory system.
• IFPMA (International Federation of Pharmaceutical Manufacturers & Associations): The global pharma industry association headquartered in Geneva. Comparable to EFPIA and IFPA in function, but at a global level representing innovative pharma companies across regions including Lithuania via its national association network.

Emerging players

• BIO (Biotechnology Innovation Organization): The world's largest biotech advocacy organization representing innovative biopharmaceutical companies. A peer in the sense of advancing innovative medicine policy, though with a heavier biotech and US-centric focus than IFPA's branded pharma remit.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/ifpa-lietuva

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IFPA - Inovatyvios farmacijos pramonės asociacija